Related Experiment Videos

p38 MAPK regulates the expression of ether à go-go potassium channel in human osteosarcoma cells

Xinyu Wu1, Daixing Zhong, Bin Lin

  • 1Department of Neurology, the Affiliated Southeast Hospital of Xiamen University, Zhangzhou, China.

Radiology and Oncology
|March 2, 2013
PubMed
Abstract

Insights

The ether à go-go (Eag) channel acts as an oncogene, promoting osteosarcoma cell growth. Its overexpression is regulated by the p38 MAPK/p53 pathway, offering potential therapeutic targets.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Signaling

Background:

  • Ether à go-go (Eag) channels are overexpressed in various cancers, but their role in osteosarcoma is unclear.
  • Mechanisms driving Eag overexpression in cancer remain largely unknown.

Purpose of the Study:

  • To investigate the expression and function of the Eag channel in human osteosarcoma cells.
  • To elucidate the molecular pathways regulating Eag expression in osteosarcoma.

Main Methods:

  • Eag expression was analyzed in MG-63 cells using RT-PCR and Western blot.
  • Cell proliferation was assessed after Eag inhibition (imipramine, shRNA) in vitro and in vivo xenograft models.
  • MAPK pathway activation and p53 levels were examined via Western blot.

Main Results:

  • Eag was significantly overexpressed in MG-63 osteosarcoma cells.
  • Inhibition of Eag or p38 MAPK suppressed cell proliferation both in vitro and in vivo.
  • p38 MAPK inhibition reduced Eag levels and increased p53 levels; p53 activation inhibited cell growth and decreased Eag levels.

Conclusions:

  • The Eag channel functions as an oncogene, promoting human osteosarcoma cell proliferation.
  • p38 MAPK and p53 signaling pathways regulate Eag expression in osteosarcoma.
Keywords:
Ether à go-goMAPK pathwaycell proliferationosteosarcomap53

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...